文献速递神经头颈MR

弥散加权与动态磁敏感对比MR成像鉴别胶质母细胞瘤非强化肿瘤与血管源性水肿

Differentiation between Nonenhancing Tumor in Glioblastoma and Vasogenic Edema Using Diffusion-Weighted and Dynamic Susceptibility Contrast MR Imaging.
PubMed 文献 · AJNR Am J Neuroradiol · 2025-10-01

回顾性分析111例胶质母细胞瘤患者的预处理MRI,比较实性非强化胶质母细胞瘤与血管源性水肿的ADC和rCBV值,并与年龄性别匹配的30例脑转移瘤比较。实性非强化胶质母细胞瘤ADC较低(1.08 vs 1.74 ×10-3 mm2/s)、rCBV较高(2.4 vs 0.30),鉴别最佳阈值ADC 1.36×10-3 mm2/s和rCBV 1.04,敏感度0.93-1、特异度1。瘤周T2-FLAIR高信号ADC与血管源性水肿相似(1.67 vs 1.74 ×10-3 mm2/s,P=.32)但rCBV较高(0.60 vs 0.30,P=.03),rCBV阈值0.42鉴别瘤周浸润与纯血管源性水肿特异度86%。

要点

  • 实性非强化胶质母细胞瘤ADC低于血管源性水肿,rCBV高于血管源性水肿,P<.001。
  • 鉴别实性非强化胶质母细胞瘤与血管源性水肿的最佳ADC阈值为1.36×10-3 mm2/s,rCBV阈值为1.04,敏感度0.93-1、特异度1。
  • 强化胶质母细胞瘤瘤周T2-FLAIR高信号rCBV高于纯血管源性水肿(0.60 vs 0.30,P=.03),rCBV阈值0.42鉴别瘤周肿瘤浸润与纯血管源性水肿特异度86%。

核心结论

  • 弥散加权和灌注加权MR成像,特别是ADC和rCBV测量,为鉴别非强化胶质母细胞瘤与血管源性水肿提供了有价值的生物标志物,所识别的阈值可能有助于胶质母细胞瘤表征、改善术前与转移瘤的鉴别并支持更精确的图像引导临床管理。

研究设计与样本

  • 回顾性分析2022年1月1日至2023年12月31日诊断为胶质母细胞瘤且有可用预处理MRI的111例患者,包括13例患者的15个实性非强化胶质母细胞瘤病灶和98例强化胶质母细胞瘤周围瘤周非强化T2-FLAIR高信号患者,并与年龄和性别匹配于实性非强化胶质母细胞瘤病灶的30个脑转移瘤病灶比较ADC和rCBV值,采用受试者工作特征分析确定最佳ADC和rCBV分类阈值。

关键影像表现/征象

  • 实性非强化胶质母细胞瘤平均ADC值为1.08(SD,0.22)×10-3 mm2/s,血管源性水肿为1.74(SD,0.17)×10-3 mm2/s,前者显著低于后者(P<.001)。
  • 实性非强化胶质母细胞瘤平均rCBV值为2.4(SD,0.86),血管源性水肿为0.30(SD,0.13),前者显著高于后者(P<.001)。
  • 强化胶质母细胞瘤周围瘤周非强化T2-FLAIR高信号ADC值为1.67(SD,0.33)×10-3 mm2/s,血管源性水肿为1.74(SD,0.17)×10-3 mm2/s,两者相似(P=.32)。
  • 强化胶质母细胞瘤周围瘤周非强化T2-FLAIR高信号rCBV值为0.60(SD,0.61),血管源性水肿为0.30(SD,0.13),前者显著高于后者(P=.03)。

诊断标准与关键数值

  • 鉴别实性非强化胶质母细胞瘤与血管源性水肿的最佳ADC阈值为1.36×10-3 mm2/s,rCBV阈值为1.04,达到优秀敏感度(0.93-1)和特异度(1)。
  • rCBV阈值0.42鉴别瘤周肿瘤浸润与纯血管源性水肿,特异度86%。

临床应用与阅片要点

  • 作者认为ADC和rCBV测量提供的阈值可能增强胶质母细胞瘤表征、改善术前与转移瘤的鉴别并支持更精确的图像引导临床管理。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND AND PURPOSE: Differentiating nonenhancing glioblastoma from vasogenic edema remains a challenge in neuroimaging. This study evaluates the utility of diffusion-weighted and dynamic susceptibility contrast MR imaging, particularly ADC and relative CBV (rCBV), in distinguishing these entities.

MATERIALS AND METHODS: We retrospectively analyzed 111 patients diagnosed with glioblastoma with available pretreatment MRIs from January 1, 2022, to December 31, 2023, including 13 patients with 15 solid, nonenhancing glioblastoma lesions and 98 patients with perilesional nonenhancing T2-FLAIR hyperintensity surrounding enhancing glioblastomas. Their ADC and rCBV values were compared with those of 30 brain metastatic lesions age- and sex-matched to solid, nonenhancing glioblastoma lesions. Receiver operating characteristic analysis was performed to determine optimal ADC and rCBV thresholds for classification.

RESULTS: Solid, nonenhancing glioblastomas had significantly lower mean ADC values and higher mean rCBV values compared with vasogenic edema (1.08 [SD, 0.22] × 10-3 versus 1.74 [SD, 0.17] × 10-3 mm2/s and 2.4 [SD, 0.86] versus 0.30 [SD, 0.13], respectively; P < .001). The optimal ADC and rCBV cutoffs for differentiating solid, nonenhancing glioblastoma from vasogenic edema were 1.36 × 10-3 mm2/s and 1.04, achieving excellent sensitivity (0.93-1) and specificity (1). Perilesional nonenhancing T2-FLAIR hyperintensity around enhancing glioblastomas had ADC values similar to those of vasogenic edema (1.67 [SD, 0.33] × 10-3 versus 1.74 [SD, 0.17] × 10-3 mm2/s; P = .32) but significantly higher rCBV (0.60 [SD, 0.61] versus 0.30 [SD, 0.13]; P = .03). An rCBV cutoff value of 0.42 distinguished perilesional tumor infiltration from pure vasogenic edema with 86% specificity.

CONCLUSIONS: Diffusion- and perfusion-weighted MR imaging, particularly ADC and rCBV measurements, provide valuable biomarkers for differentiating nonenhancing glioblastoma from vasogenic edema. The identified threshold values may enhance glioblastoma characterization, improve preoperative differentiation from metastases, and support more precise, image-guided clinical management.

来源:AJNR Am J Neuroradiol,查看原文。版权归原作者所有。

引用

  1. Alizada S, Aly Y, Bao H, et al. Differentiation between Nonenhancing Tumor in Glioblastoma and Vasogenic Edema Using Diffusion-Weighted and Dynamic Susceptibility Contrast MR Imaging. AJNR Am J Neuroradiol. 2025. PMID: 40968014. doi:10.3174/ajnr.A8788

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。